Actos Warnings and Safety Alerts
FDA Safety Alert: Risk of Bladder Cancer 40 Percent Greater in Patients Taking Actos for Longer than One Year
The Food and Drug Administration (FDA) issued a safety announcement warning that prolonged use and increased dose of Actos (pioglitazone) has been linked to a 40 percent increased risk of bladder cancer.
Actos, manufactured by Japanese pharmaceutical company Takeda Pharmaceuticals, is a drug given to millions of patients worldwide to treat type II diabetes.
The FDA reviewed preliminary data from an ongoing 10-year observational study, funded by Takeda, which is designed to evaluate whether Actos (pioglitazone) is linked to an increased risk of bladder cancer by observing diabetic patients from the Kaiser Permanente Northern California (KPNC) health plan. During its review of the data, the FDA found that patients taking pioglitazone for longer than one year were 40 percent more likely to develop bladder cancer then patients who had not been exposed to the medication. The analysis of the data also found that higher doses of pioglitazone could increase the risk of bladder cancer.
The risk of bladder cancer increased with increasing dose and duration of pioglitazone use. Compared to never being exposed to pioglitazone, a duration of pioglitazone therapy longer than 12 months was associated with a 40% increase in risk,” the agency reported.
In its safety announcement, the FDA also cited findings from animal studies and clinical trials that “suggest this is a potential safety risk that needs further study.” In lieu of the recent statistical associations between pioglitazone and bladder cancer, the FDA has recommended that physicians not prescribe the diabetes medication to anyone with active bladder cancer or a history of bladder cancer.
The FDA stopped short of recalling Actos even after France and Germany decided to suspend the use of drugs containing pioglitazone. Both countries decided to suspend the drug after a French study showed a statistically significant risk for bladder cancer among patients taking pioglitazone. The Warnings and Precautions section of Actos label, as well as the patient Medication Guide, will be revised to include the new information regarding bladder cancer risk.
Testimonials
From the very first contact with them, I felt without a doubt that I was in good, capable hands.
Your firm was with us every step of the way during a very trying time in our lives. We know we chose an excellent Law Firm to represent us.
It would be impossible to explain in this short letter the impact that the Baum Hedlund team has had on our lives. They guided us, through the most painful and difficult time in our lives, to an outcome that was the best we could ever have hoped for...
Once we read your literature we felt you were the powerhouse we needed.
While pounding away with all the legal issues you never seemed to lose track of the real people in those issues.
Thank goodness there are people like you who are so knowledgeable and compassionate.
I have given a lot of thought to how to say "thank you." Nothing special enough comes to mind so here I am writing a standard thank-you note. However, this thank-you is anything but standard...
Families and individuals who allow you the opportunity to represent them are making an extremely wise decision.
I encountered nothing but the highest level of professionalism combined with extraordinary kindness and understanding.
There isn't much more I can muster right now----everything seems so surreal. Although our journey/fight together is winding down, y'all will never get rid of me. You are forever a part of our family and support system...
They are genuinely concerned about their clients, and truly got to know of our concerns and problems.
You were very caring to my family and went the extra mile to make sure that we were satisfied.
